CCNL1
CCNL1 (cyclin L1, also known as ania-6a) is a member of the cyclin L subfamily and a regulatory component of the cyclin L-CDK11 complex. It contributes to the control of transcription and pre-mRNA splicing in the nucleus. Browse Assay Genie's current range of CCNL1 research reagents below, or read on for the biology behind the target.
CCNL1 is a regulatory component of the cyclin L-CDK11 complex, which regulates transcription and pre-mRNA splicing. In this complex the cyclin acts as the partner of the cyclin-dependent kinase, and NCBI Gene annotates the protein as having cyclin-dependent protein serine/threonine kinase regulator activity. It is involved in the regulation of mRNA splicing via the spliceosome. Activity of the complex is inhibited by the CDK-specific inhibitor CDKN1A, also known as p21.
The CCNL1 gene encodes cyclin L1 (UniProt protein name Cyclin-L1), which belongs to the cyclin family and the cyclin L subfamily. HGNC places it in the cyclins gene group. In cells the protein is found in the nucleus, where it localises to nuclear speckles and the nucleoplasm, consistent with a role in RNA processing. Mouse and rat each have a Ccnl1 ortholog.
The alias ania-6a is also used for this gene. UniProt notes that CCNL1 may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC), which makes it a point of interest for researchers studying how cyclin-associated kinases and splicing control relate to cancer. Studies of CCNL1 therefore sit at the junction of cell-cycle-related kinase biology, transcriptional regulation and spliceosome function.
CCNL1 is involved in regulating mRNA splicing via the spliceosome, making it relevant to studies of how kinase complexes shape RNA processing.
As part of the cyclin L-CDK11 complex, CCNL1 helps regulate transcription, supporting work on cyclin-kinase control of gene expression.
CCNL1 may be a candidate proto-oncogene in head and neck squamous cell carcinomas, prompting investigation of its role in tumour biology.
The cyclin L-CDK11 complex is inhibited by CDKN1A/p21, offering a route to study how CDK inhibitors modulate nuclear kinase activity.
CCNL1 is a regulatory component of the cyclin L-CDK11 complex, which regulates transcription and pre-mRNA splicing. It acts as a cyclin-dependent protein serine/threonine kinase regulator, and the complex is inhibited by the CDK inhibitor CDKN1A/p21.
CCNL1 is the HGNC symbol for cyclin L1, listed by UniProt as Cyclin-L1. The alias ania-6a is also used. The protein belongs to the cyclin family, cyclin L subfamily, and HGNC classifies the gene within the cyclins group.
Mouse and rat both have a Ccnl1 ortholog, so the gene is conserved in common model species; check the datasheet of any product for its validated reactivity. UniProt reports that CCNL1 may be a candidate proto-oncogene in head and neck squamous cell carcinomas.
Other cyclins, the CDK11 kinase partners and CDK inhibitors linked to transcription and splicing regulation.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UK58; product specifications from Assay Genie datasheets.